Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 52,627 Shares of Stock

Posted by Nicole Kennedy on Nov 21st, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 52,627 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11. Following the sale, the insider owned 5,428,912 shares of the company’s stock, valued at approximately $5,048,888.16. This represents a 0.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $36,625.28.
On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.
On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total value of $57,325.20.
On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $89,131.98.
On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total value of $44,329.21.
On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.
On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $57,312.60.
On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80.
On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $65,886.92.

Werewolf Therapeutics Stock Performance

Shares of HOWL traded down $0.04 during mid-day trading on Friday, hitting $0.81. 563,187 shares of the company’s stock were exchanged, compared to its average volume of 502,613. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38. The stock’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.33. The firm has a market cap of $39.37 million, a price-to-earnings ratio of -0.50 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its stake in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after buying an additional 23,852 shares during the period. MPM Asset Management LLC increased its holdings in shares of Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after acquiring an additional 25,688 shares in the last quarter. MPM Bioimpact LLC raised its position in shares of Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after purchasing an additional 20,799 shares during the period. Nuveen LLC bought a new position in shares of Werewolf Therapeutics in the 1st quarter worth $71,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at $92,000. Institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Bank of America dropped their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Werewolf Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $7.75.

Check Out Our Latest Report on HOWL

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.